London School of Hygiene & Tropical Medicine

• Prof Toyin Togun and Dr Sedona Sweeney, LSHTM TB Centre directors - Welcome
• Prof Marc Lipman, UCL TB director
• Prof Liam Smeeth, Director, LSHTM
• Prof Shabbar Jaffar, Director, UCL Institute for Global Health
• Mariama Barrow, TB survivor, Gambia
• Amy McConville, TB survivor, UK

As our understanding of TB evolves, attention is turning to post-TB lung health. This session will cover the burden and definition of post-TB lung disease (PTLD), innovative therapies for PTLD, and the experiences of paediatric TB survivors, highlighting both scientific advancements and personal insights.

Chairs: Prof Jayne Sutherland, MRC Gambia, Dr Jess Potter, UCL

• Overview of post-TB disability - Dr Claire Calderwood, LSHTM
• Host-directed therapy to reduce post-TB lung disease - who/how/when should we target? - Dr Gabriele Pollara, UCL

• Sequelae and lived experiences of paediatric pulmonary TB survivors - Dr Esin Nkereuwem, MRC Gambia at LSHTM

TB rates in the UK and globally are now rising, whilst demands on over-stretched resources and finances continue to increase. How should the UK respond to this, both on a national and international level?

Chairs: Dr Emily Shaw, HTD & UCLH/UKHSA, Sahera Ramzan, Results UK

• Current trends of TB in England and future national policy options - Lauren Ahyow, UKHSA TB Unit
• Understanding the global policy and funding landscape: how to drive progress in 2025 - Janika Hauser, Global Health Campaigns/Global TB Caucus
• UK place in international TB policy and financial aid - Simon Lee, Disease Poverty Policy Lead, Foreign, Commonwealth & Development Office 

Panel discussion 

• Dr Eliud Wandwalo, Global Fund to Fight AIDS, Tuberculosis, and Malaria
• Lord Nick Herbert, co-chair All-Party Parliamentary Group (APPG) on Global Tuberculosis and chair, Global TB Caucus 

Pan-TB regimens aim to revolutionise the treatment of tuberculosis by developing universal, shorter, and more effective drug combinations that can treat all forms of TB, i.e. disease caused by drug-sensitive and drug-resistant strains, thereby simplifying treatments for healthcare systems and people with TB. But is this approach doomed to failure; will it create more problems than it solves? Hear compelling arguments from experts on both sides about the challenges, potential, and future of PAN-TB in the global fight against TB, and have your say.

Chair: Dr Padmasayee Papineni, Consultant in Infectious Diseases and Acute Medicine, London North West University Healthcare NHS Trust

• For the motion: Prof Gwen Knight, LSHTM
• Against the motion: Prof Gerry Davies, University of Liverpool 

Chair: Katherine Horton, LSHTM

• Sex differences in the risk of Mycobacterium tuberculosis infection: a systematic review and meta-analysis - Dr Hannah Rickman, LSHTM
• Double burden, single approach: Integrating TB and NCD care in households affected by TB - Dr Yohhei Hamada, UCL
• The effect of N-acetyl cysteine (NAC) on oxidative pathways leading to lung damage in Tuberculosis (TB) - Ms Janet Zambezi, MRC Unit The Gambia
• Within-country heterogeneity in patterns of social contact relevant for tuberculosis infection transmission, prevention, and care - Ms Kate LeGrand, LSHTM
• The TB-HEART study: burden and natural history of cardiac pathology among participants with pulmonary TB living with and without HIV in Zambia - Dr Marcello Scopazzini, LSHTM/Zambart
• Riboswitches, sentinels at the host-pathogen interface - Dr Shahida Rafique, UCL  
• Estimating the global burden of viable Mycobacterium tuberculosis infection - Dr Alvaro Schwalb, LSHTM
• Novel inhibitors of mycobactin to combat drug-resistant TB - Mr Gourav Rakshit, Birkbeck, University of London
• Development of a predictive score to identify vulnerable households of newly diagnosed individuals with pulmonary tuberculosis in rural South Africa - Dr Indira Govender, LSHTM
• Immune Dysregulation in Post-Tuberculosis Lung Disease - Mr Raphael Kamngona, MRC Unit The Gambia
• The potential importance of TB vaccine efficacy by TB disease stage for the full value of new TB vaccines - Dr Rebecca Clark, LSHTM
• Mycobacterium tuberculosis complex strain discordance among household index-secondary patient pairs, a systematic review and meta-analysis - Mrs Martha Chipinduro, THRU ZIM

With the recognition by the World Health Organisation of asymptomatic (nee subclinical) TB, we are entering a new phase in TB policy and research. This session will provide an update on where this field is, and where it is likely to go in the coming years.

Chairs: Prof Rein Houben, LSHTM, Prof Helen Ayles, LSHTM

• Policy - Updates on definitions, terminology and policy landscape for asymptomatic TB - Dr Katherine Horton, LSHTM
• Screening and diagnosis - how good or bad are we at diagnosing early disease states of TB - Dr Alvaro Schwalb, LSHTM
• Biomarkers - How do we evaluate biomarkers for asymptomatic TB? - Dr James Greenan-Barrett, UCL
• Treatment - The Treatment of Early TB states - Dr Hanif Esmail, UCL